Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma

Sorigue, Marc; Bishton, Mark; Domingo-Domenech, Eva; McMillan, Andrew; Prusila, Roosa; García, Olga; Kuusisto, Milla; Condom, Maria; Tapia, Gustavo; Ribera, Josep-María; Kuittinen, Outi; Fox, Christopher P; Sancho, Juan-Manuel

doi:10.1080/10428194.2019.1594212

All Outputs (5)

Re: Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case Control Study (2019)
Journal Article

How can gene-editing of human pluripotent stem cells help cystic fibrosis? (2019)
Journal Article

Cystic fibrosis (CF) is a monogenic recessive disorder, affecting 70,000 people worldwide. CF is due to mutations in the CFTR gene, resulting in a defective protein that leads to symptoms in numerous organs, especially lungs. Despite recent advances,... Read More about How can gene-editing of human pluripotent stem cells help cystic fibrosis?.

Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study (2019)
Journal Article

IMPORTANCE Anticholinergic medicines have short-term cognitive adverse effects, but it is uncertain whether long-term use of these drugs is associated with an increased risk of dementia. OBJECTIVE To assess associations between anticholinergic dr... Read More about Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study.

Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges (2019)
Journal Article

Nonalcoholic fatty liver disease (NAFLD) is now the leading cause of chronic liver disease in industrialized economies. With no licensed treatment currently available, together with a growing prevalence that parallels global increases in obesity and... Read More about Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges.

Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma (2019)
Journal Article

Short responses to immunochemotherapy predict for an inferior OS in follicular lymphoma. We set out to determine whether this is also the case in marginal zone lymphoma. A group of 139 marginal zone lymphoma (MZL) patients treated with front-line imm... Read More about Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma.